Nystatin Oral Suspension

Manufacturer
Xttrium Laboratories, Inc.
Effective date
2026-02-06
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
1
Source
full-release
Hydrated at
2026-05-31 22:05:50

Label at a glance#

ProductNystatin Oral Suspension
Active ingredientNYSTATIN
Label structure13 sections

Indications and uses

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

Dosage and administration

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes). NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective. CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). T...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx Only

DESCRIPTION

DESCRIPTION SECTION

Nystatin is an antimycotic polyene antibiotic obtained from Streptomyces noursei.

Structural formula:

nystatin chemical structurenystatin chemical structure

C 47H 75NO 17 MW 926.13

Nystatin Oral Suspension USP, for oral administration, contains 100,000 USP Nystatin Units per mL. Inactive ingredients: alcohol (≤ 1% v/v), artificial wild cherry flavor, banana flavor, D&C Yellow #10, FD&C Red #40, glycerin, USP, magnesium aluminum silicate, methylparaben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%. May also contain citric acid, USP for pH adjustment.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Pharmacokinetics

PHARMACOKINETICS SECTION

Gastrointestinal absorption of nystatin is insignificant. Most orally administered nystatin is passed unchanged in the stool. In patients with renal insufficiency receiving oral therapy with conventional dosage forms, significant plasma concentrations of nystatin may occasionally occur.

Microbiology

MICROBIOLOGY SECTION

Nystatin is both fungistatic and fungicidal in vitro against a wide variety of yeasts and yeast-like fungi. Candida albicans demonstrates no significant resistance to nystatin in vitro on repeated subculture in increasing levels of nystatin; other Candida species become quite resistant. Generally, resistance does not develop in vivo. Nystatin acts by binding to sterols in the cell membrane of susceptible Candida species with a resultant change in membrane permeability allowing leakage of intracellular components. Nystatin exhibits no appreciable activity against bacteria, protozoa, or viruses.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Nystatin Oral Suspension is indicated for the treatment of candidiasis in the oral cavity.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

The preparation is contraindicated in patients with a history of hypersensitivity to any of its components.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

This medication is not to be used for the treatment of systemic mycoses. Discontinue treatment if sensitization or irritation is reported during use.

Carcinogenesis, Mutagenesis, Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

No long-term animal studies have been performed to evaluate carcinogenic potential. There also have been no studies to determine mutagenicity or whether this medication affects fertility in males or females.

Pregnancy

PREGNANCY SECTION

Teratogenic Effects

TERATOGENIC EFFECTS SECTION

Animal reproduction studies have not been conducted with nystatin oral suspension. It is also not known whether nystatin oral suspension can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Nystatin oral suspension should be given to a pregnant woman only if clearly needed.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether nystatin is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when nystatin is administered to a nursing woman.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Nystatin is well tolerated even with prolonged therapy. Oral irritation and sensitization have been reported. (See PRECAUTIONS: General).

Gastrointestinal:Diarrhea (including one case of bloody diarrhea), nausea, vomiting, gastrointestinal upset/disturbances.

Dermatologic:Rash, including urticaria has been reported rarely. Stevens-Johnson syndrome has been reported very rarely.

Other:Tachycardia, bronchospasm, facial swelling, and non-specific myalgia have also been rarely reported.

To report SUSPECTED ADVERSE REACTIONS, contact Xttrium Laboratories, Inc. at 1-800-587-3721 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

OVERDOSAGE

OVERDOSAGE SECTION

Oral doses of nystatin in excess of five million units daily have caused nausea and gastrointestinal upset. There have been no reports of serious toxic effects of superinfections (See CLINICAL PHARMACOLOGY, Pharmacokinetics).

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

INFANTS: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).

NOTE: Limited clinical studies in premature and low birth weight infants indicate that 1 mL four times daily is effective.

CHILDREN AND ADULTS: 4-6 mL (400,000 to 600,000 units) four times daily (one-half of dose in each side of mouth). The preparation should be retained in the mouth as long as possible before swallowing.

Continue treatment for at least 48 hours after perioral symptoms have disappeared and cultures demonstrate eradication of Candida albicans.

HOW SUPPLIED

HOW SUPPLIED SECTION

Nystatin Oral Suspension USP, 100,000 USP Nystatin Units per mL, is available as a fruit flavored, light creamy yellow, ready-to-use suspension.

60 mL bottle was a calibrated dropper and

1 Pint (473 mL) bottles (0116-4026-16)

Storage

STORAGE AND HANDLING SECTION

Store at 20° to 25°C (68° to 77°F) [See USP Controlled Room Temperature].

Avoid freezing.

SPL UNCLASSIFIED SECTION

Rx Only
Product No.: 4026
Manufactured By:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056
402616BTLLBL
REV. 09-25

PRINCIPAL DISPLAY PANEL - 60 mL Bottle Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

NDC 0116-4026-16

NYSTATIN ORAL SUSPENSION, USP

(100,000 units per mL)

Each mL contains: 100,000 units Nystatin, USP with the following inactive ingredients: alcohol (≤ 1% v/v), artificial wild cherry flavor, banana flavor, D&C yellow #10, FD&C red #40, glycerin, USP, magnesium aluminum silicate, methyl paraben, NF, potassium phosphate dibasic, USP, propylene glycol, USP, propylparaben, NF, purified water, USP and sucrose 33.5%.
May also contain citric acid, USP for Ph adjustment.
Fruit Flavored
SHAKE WELL BEFORE USING
Rx Only
NET: 1 Pint (473 mL)

USUAL DOSAGE: For infants: 2 mL (200,000 units) four times daily (in infants and young children, use dropper to place one-half of dose in each side of mouth and avoid feeding for 5 to 10 minutes).
USUAL DOSAGE: For Children and Adults: See package insert.
WARNINGS: Keep this and all drugs out of the reach of children.
In case of accidental overdose, seek professional assistance or contact a Poison Control Center immediately.
Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature].
AVOID FREEZING
Dispense in a tight, light-resistant container as defined in the USP.
Manufactured by:
Xttrium Laboratories, Inc.
1200 E. Business Center Dr.
Mount Prospect, IL 60056
402616BTLLBL REV. 09-25

16 oz bottle label16 oz bottle label

PRINCIPAL DISPLAY PANEL - 5 mL Unit Dose Cup Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

UNIT DOSE

Delivers 5 mL
NDC 0116-4026-05
NYSTATIN
ORAL SUSPENSION, USP
500,000 units / 5 mL
Alcohol ≤ 1% v/v SHAKE WELL

Institutional Use Only

Rx Only

Xttrium Laboratories, Inc.

Mount Prospect, IL

SEE INSERT

lidlid

insertinsert

insertinsert

insertinsert

insertinsert

DailyMed RxNorm Mappings#

RxCUI, RxNorm string, TTY table
RxCUIRxNorm stringTTYSPL version
312055nystatin 100,000 UNT/mL Oral SuspensionPSN1
312055nystatin 100000 UNT/ML Oral SuspensionSCD1
312055nystatin 100,000 UNT/ML Oral SuspensionSY1
312055nystatin 500,000 UNT per 5 ML Oral SuspensionSY1

DailyMed Pharmacologic Classes#

Class, Version, Type table
ClassVersionTypeEffective
NYSTATIN Pharmacologic Class Indexing2Indexing - Pharmacologic Class20180813

Product Linked Resources#

Resource, Code type, Value table
ResourceCode typeValueEquivalent identifiersSource image
Data codeCode 128301164026050Nystatin UD Lid.jpg

DailyMed Product Concepts#

Product concept, Relation, Version table
Product conceptRelationVersionEffective
e29fe634-dc25-094c-c77f-5d09c3eceb3eProduct name520260107
4b7700e3-6e0e-45e5-9d22-6f754d61386eProduct name220250304
e57b6340-9387-3f9a-7307-511c81791375Product name320221214
544f8e8d-6389-eeeb-9586-aa447c08dcc7Product name520210614
1629e00f-54fb-4a43-8306-b58442b23902Product name920200430
854ec07b-1cd7-a5db-235a-7aa24d3cf97aProduct name320180628
19b9f4c1-15e9-edcc-4c16-f01ecfb5c549Product name120140508

DailyMed Package Descriptions#

Package NDC, Product, Description table
Package NDCProductDescriptionFormQuantityStrengthSPL version
0116-4026-05Nystatin Oral Suspension5 mL in 1 CUP, UNIT-DOSESUSPENSION51
0116-4026-11Nystatin Oral Suspension10 in 1 TRAYSUSPENSION101
0116-4026-11Nystatin Oral Suspension10 in 1 CASESUSPENSION101
0116-4026-16Nystatin Oral Suspension473 mL in 1 BOTTLE, PLASTICSUSPENSION4731
0116-4026-50Nystatin Oral Suspension10 in 1 TRAYSUSPENSION101
0116-4026-50Nystatin Oral Suspension5 in 1 CASESUSPENSION51

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 16 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
0116-40260116-4026-16, 0116-4026-05, 0116-4026-50, 0116-4026-11

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 15 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
A062512-001NYSTATINNYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
A062512-001AA

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29c2088c7a36db…
2026-09-14 22:38:342026-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2984e616aacf4f…
2026-08-18 06:07:402026-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2931067a03dcf5…
2025-08-23 18:47 UTC2025-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-296a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2903ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-292680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-295bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-29d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAA1984-10-2979d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-291e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-298072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-294b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-2974a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-2987673890dc5c…
2021-03-12 10:30 UTC2021-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-295aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-298869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293f01610625f2…
2019-09-15 20:21 UTC2019-09A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29b00525d2431f…
2019-07-19 19:46 UTC2019-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-296a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-291c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-299b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293f0d92c62455…
2023-05-13 08:27 UTC2023-05A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-29053a50430f4f…
2023-01-26 05:58 UTC2023-01A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062512-001NYSTATIN100,000 UNITS/MLSUSPENSION / ORALAARS1984-10-293a93d1ddd44b…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-10-15 13:18:302026-09A062512-001AA1c2088c7a36db…
2026-09-14 22:38:342026-08A062512-001AA184e616aacf4f…
2026-08-18 06:07:402026-07A062512-001AA1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02A062512-001AA1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12A062512-001AA131067a03dcf5…
2025-08-23 18:47 UTC2025-08A062512-001AA16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03A062512-001AA1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02A062512-001AA1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01A062512-001AA103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12A062512-001AA12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09A062512-001AA15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11A062512-001AA1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10A062512-001AA1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08A062512-001AA179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07A062512-001AA1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06A062512-001AA11e350fbaab3a…
2024-05-31 18:47 UTC2024-05A062512-001AA18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06A062512-001AA15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04A062512-001AA15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04A062512-001AA14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12A062512-001AA174a2ff9319b5…
2022-03-09 01:35 UTC2022-03A062512-001AA1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12A062512-001AA1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05A062512-001AA187673890dc5c…
2021-03-12 10:30 UTC2021-03A062512-001AA15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12A062512-001AA18869cabd3fbd…
2020-11-12 02:37 UTC2020-11A062512-001AA1c0c555d07b60…
2019-12-14 00:12 UTC2019-12A062512-001AA13f01610625f2…
2019-09-15 20:21 UTC2019-09A062512-001AA1b00525d2431f…
2019-07-19 19:46 UTC2019-07A062512-001AA1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03A062512-001AA16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02A062512-001AA11c564ffb4f44…
2023-12-20 04:57 UTC2023-12A062512-001AA1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11A062512-001AA1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10A062512-001AA19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07A062512-001AA1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06A062512-001AA13f0d92c62455…
2023-05-13 08:27 UTC2023-05A062512-001AA1053a50430f4f…
2023-01-26 05:58 UTC2023-01A062512-001AA13bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11A062512-001AA13a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Nystatin Oral SuspensionNYSTATINXttrium Laboratories, Inc.4a670371-d373-1ba6-e063-6394a90a13b62026-02-06Adverse reactionsExact identifier
ndc (package): 0116-4026-05
ndc (package): 0116-4026-50
ndc (package): 0116-4026-11
ndc (package): 0116-4026-16
ndc (product): 0116-4026
ndc11 (package): 00116402616
ndc11 (package): 00116402605
ndc11 (package): 00116402611
ndc11 (package): 00116402650
spl id: 4a2ff89a-52fe-8bf9-e063-6394a90a7f1d
spl set id: 4a670371-d373-1ba6-e063-6394a90a13b6

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.